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Mitochondrial ﬁssion, fusion and biogenesisThemain purpose of this studywas to examinewhether streptozotocin (STZ)-induced type 1 diabetes (T1D) and
insulin (INS) treatment affect mitochondrial function, ﬁssion/fusion and biogenesis, autophagy and tau protein
phosphorylation in cerebral cortex from diabetic rats treated or not with INS. No signiﬁcant alterations were
observed in mitochondrial function as well as pyruvate levels, despite the signiﬁcant increase in glucose levels
observed in INS-treated diabetic rats. A signiﬁcant increase in DRP1 protein phosphorylated at Ser616 residue
was observed in the brain cortex of STZ rats. Also an increase in NRF2 protein levels and in the number of
copies of mtDNAwere observed in STZ diabetic rats, these alterations being normalized by INS. A slight decrease
in LC3-II levels was observed in INS-treated rats when compared to STZ diabetic animals. An increase in tau
protein phosphorylation at Ser396 residue was observed in STZ diabetic rats while INS treatment partially
reversed that effect. Accordingly, a modest reduction in the activation of GSK3β and a signiﬁcant increase in
the activity of phosphatase 2A were found in INS-treated rats when compared to STZ diabetic animals. No
signiﬁcant alterationswere observed in caspases 9 and 3 activity and synaptophysin and PSD95 levels. Altogether
our results show thatmitochondrial alterations induced by T1D seem to involve compensationmechanisms since
no signiﬁcant changes in mitochondrial function and synaptic integrity were observed in diabetic animals. In
addition, INS treatment is able to normalize the alterations induced by T1D supporting the importance of INS
signaling in the brain.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Type 1 diabetes (T1D) is ametabolic disease that originates from the
autoimmune destruction of β-cells due to lymphocytic inﬁltration of
pancreatic islets, resulting in the permanent dependency of patients
on exogenous insulin (INS) to survive [1].
Cognitive deﬁcits, such as impaired learning,memory, problem solv-
ing, andmentalﬂexibility have been recognized as beingmore common
in T1D subjects than in the general population [2,3]. It has also been
demonstrated that T1D exacerbates tau protein hyperphosphorylation
and amyloid beta (Aβ) formation contributing to the deposition of
neuroﬁbrillary tangles and Aβ plaques, the two major pathologicalculty of Medicine, University of
iversity of Coimbra, 3004-517
pt (P.I. Moreira).hallmarks of Alzheimer's disease (AD), in the amyloid precursor protein
(APP) transgenic mice [4].
INS has been proven to exert a role in synaptic plasticity and mem-
ory consolidation through the modulation of the activity of excitatory
and inhibitory receptors such as those for glutamate and GABA, and
by triggering signal transduction cascades leading to the alteration of
gene expression [5,6]. Furthermore, INS and insulin-like growth factors
(IGFs) have been shown to protect neurons against Aβ toxicity [7,8].
Likewise, insulin reduced tau protein phosphorylation and promoted
its binding to microtubules, the effects of INS being mediated through
the inhibition of glycogen synthase kinase-3β (GSK-3β) via the
phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway [9].
Mitochondria account for more than 90% of the cellular energy
production [10]. This bioenergetic production assumes its maximum
importance in the brain since neurons have a high energy demand
and a limited glycolytic capacity, making them highly dependent on
aerobic oxidative phosphorylation [11].
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tween mitochondrial ﬁssion and fusion. Mitochondrial ﬁssion is
governed by dynamin-like protein 1 (DRP1), a large cytosolic GTPase
that is recruited to the mitochondrial membrane upon a ﬁssion-like
stimuli, and by Fis1, a small mitochondrial molecule located in the
outer membrane [12]. In turn, mitochondrial fusion is directed by
three large GTPases, Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2), both
located in the mitochondrial outer membrane, and optic atrophy 1
(OPA1) protein, located in the inner mitochondrial membrane [12].
Mitochondrial biogenesis results froman intricate crosstalk between
both nuclear andmitochondrial genomes. Themolecularmachinery un-
derlyingmitochondrial biogenesis is constituted by the nuclear respira-
tory factor 1 (NRF 1) and nuclear respiratory factor 2 (NRF 2), which
control thenuclear genes that encodemitochondrial proteins, andmito-
chondrial transcription factor A (TFAM) that drives transcription and
replication of mitochondrial (mt) DNA [13,14]. The expression of
NRF1, NRF2, and TFAM is regulated by the peroxisome proliferator acti-
vator receptor gamma-coactivator 1α (PGC-1α) [15].
Autophagy is an evolutionarily conserved housekeeping process that
enables cells to get nutrients through the digestion of their own
components and, at the same time, degradesmisfolded proteins and ag-
gregates, damaged organelles and invading microorganisms [16]. Au-
tophagy is a tightly regulated process in a multistep manner. To the
level of vesicle nucleation/initiation two main proteins are involved:
themammalian target of rapamycin (mTOR),which is an autophagic re-
pressor; and Beclin 1, which is an autophagic inducer [17]. Regarding
membrane elongation, cytosolic LC3-I is transformed to a membrane-
bound form, LC3-II [17]. In the autophagic degradation of ubiquitinated
protein aggregates inmammalian cells, LC3 interacts with p62, which is
a ubiquitin-binding protein therefore being considered an autophagic
substrate [17].
The main aim of this study was the evaluation of the effects of
streptozotocin (STZ)-induced T1D and INS treatment on brain cortical
mitochondria, autophagy and tau protein phosphorylation.We evaluat-
ed several mitochondrial parameters: respiration [respiratory control
ratio (RCR), and ADP/O index], phosphorylation system [transmem-
brane potential (ΔΨm), ADP-induced depolarization, repolarization
lag phase], ﬁssion/fusion protein levels (DRP1, Fis 1 and OPA1, MFN1,
MFN2, respectively), and biogenesis (NRF1, NRF2, TFAM and the num-
ber of copies of mtDNA). Autophagy (mTOR, Beclin1, LC3 and p62 pro-
tein levels), the activity of several kinases and phosphatase 2A that
modulate tau protein phosphorylation, activity of caspases 3 and 9
and protein levels of synaptophysin and PSD95 were also evaluated.
2. Material and methods
2.1. Reagents
STZ was obtained from Sigma Aldrich (St. Louis, MO, USA). INS
(Humulin NPH) was obtained from Eli Lilly and Company (USA). All
the chemicals used were of the highest grade of purity commercially
available.
2.2. Animal housing and treatment
Seventeen male Wistar rats (2-month-old) purchased from Charles
River were housed in our Animal Facility (Laboratory Research Center,
Faculty of Medicine, University of Coimbra) and maintained under con-
trolled light (12 h day/night cycle) and humidity with ad libitum access
towater and powdered rodent chow (except in the fasting period). Rats
were deprived of food overnight and randomly divided into two groups.
One group of eleven animals received an intraperitoneal (i.p.) injection
of STZ (50 mg/kg body weight) freshly dissolved in 100mM citrate, pH
4.5. The volume administered was always 0.5 ml/200 g body weight.
The control group (six animals) received an i.p. injection with an
equal volume of citrate (vehicle solution). In the following 24 h, animalswere provided with free access to glycosylated serum in order to avoid
hypoglycemia resulting from the massive destruction of β-cells and
consequent release of intracellular insulin associated with STZ treat-
ment [18]. Three days after STZ administration, the tail vein blood
glucose levels were measured in all animals and those presenting levels
above 250 mg/dl were considered diabetic. Two months after the in-
duction of diabetes with STZ, diabetic rats were randomly divided into
two groups and one group of six animals was subjected to daily subcu-
taneous (s.c.) injections of INS, in order to lower the systemic levels of
glucose (dose adjusted to blood glucose levels as follows: if blood glu-
cose levels were ≤200 mg/dL, 2 U INS were administered to rats; if
blood glucose levels were N200 mg/dL an extra 2 U INS per each
100 mg/dL blood glucose were given to rats), during one month.
Three months after the induction of diabetes, the rats were sacriﬁced
by cervical displacement and decapitation. Animal handling and sacri-
ﬁce followed the procedures approved by the Federation of European
Laboratory Animal Science Associations (FELASA).
2.3. Measurement of blood glucose and hemoglobin A1C levels
Blood glucose was determined immediately after sacriﬁce by a glu-
cose oxidase reaction, using a glucometer (Glucometer-Elite, Bayer).
Hemoglobin A1C (HbA1c) levels were determined using Systems
SYNCHRON CX 4 (Beckman). This system utilizes two cartridges, Hb
and A1c to determine A1c concentration as a percentage of the total
Hb. The hemoglobin is measured by a colorimetric method and the
A1c concentration by a turbidimetric immunoinhibition method.
2.4. Measurement of brain INS, glucose and pyruvate levels
Brain cortical tissueswere homogenized in radioimmunoprecipitation
assay (RIPA) buffer containing 0.1 M phenylmethylsulfonyl ﬂuoride
(PMSF), 0.2 M dithiothreitol (DTT), and protease and phosphatase inhib-
itors (commercial protease and phosphatase inhibitor cocktails from
Roche Applied Science). The crude homogenate was incubated on ice
for 15 min, frozen and defrozen 3 times to favor disruption, and centri-
fuged at 14000 rpm (Eppendorf centrifuge 5415C) for 10 min, at 4 °C,
and the resulting supernatant was collected and stored at−80 °C.
INS quantiﬁcation was performed using an ELISA kit (BertinPharma,
France) according to the manufacturers' instructions. The principle of
the kit is based on the competition between unlabeled rat insulin and
acetylcholinesterase (AChE) linked to rat insulin (tracer) for limited
speciﬁc Guinea-Pig anti-rat insulin antiserum sites.
Glucose quantiﬁcation was performed using a PicoProbe™ glucose
ﬂuorometric assay kit (BioVision, USA) according to manufacturers' in-
structions. The principle of the kit is based on the enzymatic oxidation of
D-glucose to form a product which reacts with a colorless probe to gen-
erate ﬂuorescence. The ﬂuorescence generated is directly proportional
to the amount of glucose present in the sample.
Pyruvate quantiﬁcation was performed using a pyruvate colorimet-
ric assay kit (BioVision, USA) according to the manufacturers' instruc-
tions. The principle of the kit is based on the enzymatic oxidation of
pyruvate bypyruvate oxidase to generate color upon reactionwith a py-
ruvate probe. The color intensity is proportional to pyruvate content;
therefore the pyruvate concentration can be accurately measured.
2.5. Preparation of mitochondrial fractions
Brain corticalmitochondriawere isolated from rats by themethod of
Moreira et al. [19], using 0.02% digitonin to allow the release of mito-
chondria from the synaptosomal fraction. Brieﬂy, after animal decapita-
tion, the cortex was immediately separated and homogenized at 4 °C in
10 ml of isolation medium (225 mMmannitol, 75 mM sucrose, 5 mM
HEPES, 1mMEGTA, 1 mg/ml BSA, pH 7.4) containing 5mg of the bacte-
rial protease (Sigma). Single brain homogenates were brought to 30 ml
and then centrifuged at 2500 rpm (Sorvall Evolution RC Superspeed
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centrifuged at 10,000 rpm for 10 min. The pellet, including the ﬂuffy
synaptosomal layer, was resuspended in 10 ml of the isolation medium
containing 0.02% digitonin and centrifuged at 10,000 rpm for 10 min.
The brownmitochondrial pelletwithout the synaptosomal layerwas re-
suspended again in 10 ml of medium and centrifuged at 10,000 rpm for
5 min. The pellet was resuspended in 10 ml of washing medium
(225 mMmannitol, 75 mM sucrose, 5 mM HEPES, pH 7.4) and centri-
fuged at 10,000 rpm for 5min. The ﬁnalmitochondrial pellet was resus-
pended in the washing medium and the protein amount was
determined by the biuret method calibrated with bovine serum albu-
min (BSA) [20].
2.6. Measurements of mitochondrial respiration
Oxygen consumption of mitochondria was registered polarographi-
callywith a Clark oxygen electrode [21] connected to a suitable recorder
in a thermostated water-jacketed closed chamber with magnetic stir-
ring. The reactionswere carried out at 30 °C in 1ml of standard respira-
tory medium (100 mM sucrose, 100 mM KCl, 2 mM KH2PO4, 5 mM
Hepes and 10 μMEGTA; pH 7.4) with 0.5mg of protein. State 3 of respi-
ration (consumption of oxygen in the presence of substrate and ADP)
was initiated with the addition of exogenous ADP (50 nmol/mg
protein). States 3 and 4 (consumption of oxygen after ADP phosphory-
lation) of respiration, respiratory control ratio (RCR = state 3/state 4),
and ADP/O index (a marker of the mitochondrial ability to couple oxy-
gen consumption to ADP phosphorylation during state 3 of respiration)
were determined according to [22]. FCCP-stimulated respiration was
also measured as a state of uncoupled respiration, i.e. respiratory
chain maximal activity [23]. Oligomycin-inhibited respiration was also
measured representing oxygen consumption with inhibited ATP syn-
thase, which is due to proton leak [23].
2.7. Measurements of ΔΨm
The transmembrane potential (ΔΨm) was monitored by evaluating
the transmembrane distribution of the lipophilic cation TPP+
(tetraphenylphosphonium) with a TPP+-selective electrode prepared
according to Kamo et al. [24] using an Ag/AgCl-saturated electrode
(Tacussel, model MI 402) as reference. TPP+ uptake has beenmeasured
from the decreased TPP+ concentration in the medium sensed by the
electrode. The potential difference between the selective electrode and
the reference electrodewasmeasuredwith an electrometer and record-
ed continuously in a Linear 1200 recorder. The voltage response of the
TPP+ electrode to log[TPP+] was linear with a slope of 59 ± 1, which
is in a good agreementwith theNernst equation. Reactionswere carried
out in a chamberwithmagnetic stirring in 1ml of the standardmedium
(100 mM sucrose, 100 mM KCl, 2 mM KH2PO4, 5 mMHepes and 10 μM
EGTA; pH 7.4) containing 3 μMTPP+. This TPP+ concentrationwas cho-
sen in order to achieve high sensitivity in measurements and to avoid
possible toxic effects on mitochondria [25]. The ΔΨm was estimated
by the equation:ΔΨm (mV)=59 log(v/V)− 59 log(10ΔE/59− 1), as in-
dicated by Kamoet al. [24] and Muratsugu et al. [26]. v, V, and ΔE stand
for mitochondrial volume, volume of the incubation medium and de-
ﬂection of the electrode potential from the baseline, respectively. This
equationwas derived assuming that TPP+ distribution between themi-
tochondria and the medium follows the Nernst equation, and that the
law of mass conservation is applicable. A matrix volume of 1.1 μl/mg
proteinwas assumed. No correctionwasmade for the “passive” binding
contribution of TPP+ to themitochondrialmembranes, because thepur-
pose of the experiments was to show relative changes in potentials
rather than absolute values. As a consequence, we can anticipate a slight
overestimation onΔΨmvalues. However, the overestimation is only sig-
niﬁcant at ΔΨm values below 90 mV, therefore, far from our measure-
ments. Mitochondria (0.5 mg/ml) were energized with 5 mM
succinate (substrate of complex II) in the presence of 2 μM rotenonein order to activate the mitochondrial electron transport chain. After a
steady-state distribution of TPP+ had been reached (ca. 1min of record-
ing), ΔΨm ﬂuctuations were recorded.
2.8. Protein extraction for Western blot analysis
Brain cortical tissues were homogenized in RIPA buffer containing
0.1 M PMSF, 0.2 M DTT, and protease and phosphatase inhibitors
(commercial protease and phosphatase inhibitor cocktails from Roche
Applied Science). The crude homogenate was incubated on ice for 15
min, frozen and defrozen 3 times to favor disruption, and centrifuged
at 14,000 rpm (Eppendorf centrifuge 5415C) for 10 min, at 4 °C, and
the resulting supernatant was collected and stored at −80 °C. The
amount of protein content in the samples was analyzed by the
bicinchoninic acid (BCA) protein assay using the BCA kit (Pierce Thermo
Fisher Scientiﬁc, Rockford, IL).
2.9. Western blot analysis
Samples (50–75 μg per lane) were resolved by electrophoresis in 8–
15% sodium dodecyl sulfate (SDS)–polyacrylamide gels and transferred
to polyvinylidenediﬂuoride (PVDF) membranes. Non-speciﬁc binding
was blocked by gently agitating the membranes in 5% non-fat milk or
5% BSA for phosphoproteins and 0.05% Tween in Tris-buffered saline
(TBS) for 1 h at room temperature. The blots were subsequently incu-
bated with speciﬁc primary antibodies, overnight at 4 °C, with gentle
agitation. The blotswerewashed 3 times (15 min), with Tris buffer con-
taining 0.05% Tween (TBS-T) and then incubated with secondary anti-
bodies for 1 h at room temperature with gentle agitation. After 3
washes with TBS-T speciﬁc bands of immunoreactive proteins were vi-
sualized after membrane incubation with enhanced chemiﬂuorescence
(ECF) for 5min in a VersaDoc Imaging System (Bio-Rad), and the densi-
ty of protein bands was calculated using the Quantity One Program
(Bio-Rad).
In some cases, the same membrane was used to detect other pro-
teins with very different molecular weights. In these situations, the
membranes were gently washed with 40% methanol (30 min) and 3
times (15 min) with TBS-T and then incubated with the primary anti-
body. The following steps are identical to those described above.
Total and respective phosphorylated protein levels were examined
in two distinct membranes. To preserve data accuracy the following
procedures were adopted: 1) the same sample was used to analyze
total and phosphorylated protein levels; 2) all samples had the same cy-
cles of freezing and thawing (reduced to a minimum); 3) the two gels
were prepared and ran at the same time; 4) after proteins have been
transferred onto PVDFmembranes and stained with speciﬁc antibodies,
each band of interest were normalized with respect to the loading con-
trol (actin); and 5) the ratio between phosphorylated and total protein
levels was obtained by the formula (phosphorylated protein/actin
membrane 1)/(total protein/actin membrane 2).
The primary antibodies used were: anti-Pser396 Tau (1:1000; Santa
Cruz Biotechnology); anti-Pthr181 Tau (1:250; Santa Cruz Biotechnology);
anti-Tau (BT2) (1:1000; Thermo Scientiﬁc); anti-Pser9 GSK3β (1:1000;
Cell Signaling); anti-Ptyr216 GSK3β (1:500; Santa Cruz Biotechnology);
anti-GSK3β (1:500; Santa Cruz Biotechnology); anti-Pthr183/tyr185
JNK (1:2000; Cell Signaling); anti-JNK (1:1000; Cell Signaling);
anti-Pthr202/tyr204 ERK (1:1000; Cell Signaling); anti-ERK (1:1000;
Cell Signaling); anti-Pthr180/tyr182 p38 MAPK (1:1000; Cell Signal-
ing); anti-p38 MAPK (1:1000; Cell Signaling); anti-Synaptophysin
(1:20,000; Sigma Aldrich);anti-PSD95 (1:1000; Cell Signaling);
anti-Mfn1 (1:1000; Santa Cruz Biotechnology); anti-Mfn2 (1:1000;
Santa Cruz Biotechnology); anti-OPA1 (1:1000; BD Biosciences);
anti-Fis1 (1:750; Imgenex); anti-DRP1 (1:1000; BD Biosciences);
anti-Pser616 DRP1 (1:1000; Cell Signaling); anti-mTOR (1:1000; Cell
Signaling); anti-Pser2448 mTOR (1:1000; Cell Signaling); anti-Beclin
1 (1:1000; BD Biosciences); anti-LC3 (1:1000; Sigma); anti-p62
Table 1
Oligonucleotides and cycling conditions for qPCR ampliﬁcation of ND1 and β-2-
microglobulin.
Gene Sequence
(5′–3′)
AT
(°C)
Ampliﬁcon
size (bp)
C
ND1 Sense: GAG CCC TAC GAG CCG TTG CC 58 271 30
Antisense: GCG AATG GTC CTG CGG CGT A
β2MG Sense: GCG TGG GAG GAG CAT CAG GG 58 264 30
Antisense: CTC ATC ACC ACC CCG GGG ACT
Abbreviations: AT— annealing temperature; C — Number of cycles of ampliﬁcation
1157R.X. Santos et al. / Biochimica et Biophysica Acta 1842 (2014) 1154–1166(1:1000; Sigma); anti-NRF1 (1:500; Santa Cruz Biotechnology);
anti-NRF2 (1:500; Abcam); anti-TFAM (1:1000; Santa Cruz Biotech-
nology); anti-MTCOI (1:1000; Abcam); anti-α-Tubulin (1:1000; Cell
Signaling); and anti-β actin (1:5000; Sigma). The secondary anti-
bodies used were: anti-mouse IgG alkaline phosphatase conjugate
(1:10,000; Amersham Pharmacia Biotech); anti-rabbit IgG alkaline
phosphatase conjugate (1:10,000; Amersham Pharmacia Biotech);
anti-goat IgG alkaline phosphatase conjugate (1:2500; Santa Cruz
Biotechnology).
2.10. Measurement of phosphatase 2A activity
Phosphatase 2A (PP2A) activity was measured using a PP2A DuoSet
IC kit (R&D Systems) according to the manufacturer's instructions.
Brieﬂy, a portion of brain tissuewas homogenized in ice cold lysis buffer
(Cell Signaling) and 75 μg of protein were loaded onto 96-well plates
coated with a capture antibody speciﬁc for PP2A (R&D Systems) for
immunocapture at 4 °C for 3 h. Afterwashing twice, synthetic phospho-
peptide substrates (200 μM) were added for the dephosphorylation re-
action catalyzed by PP2A. The level of free phosphate was determined
by a sensitive dye-binding assay using malachite green and molybdic
acid according to themanufacturer's instructions followed bymeasure-
ment of the absorbance at 620 nm.
2.11. Measurement of caspases 3 and 9 activation
Caspases 3 and 9 activation was measured using a colorimetric
method. Brain cortical tissues were homogenized in cold RIPA buffer
and frozen and defrozen 3 times. The lysates were centrifuged for
10 min at 14,000 rpm (5417R, Eppendorf) at 4 °C. The resulting super-
natant was stored at−80 °C. Protein concentrationsweremeasured by
using the BCA protein assay kit (Pierce, Rockford, IL).
Samples (50 μg of protein)were incubated at 37 °C for 2 h in 25mM
Hepes, pH 7.5 containing 0.1% 3-[(3-cholamido-propyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 10% sucrose, 2 mM
DTT, and 40 μM Ac-DEVD-pNA for caspase 3 or 40 μM Ac-LEHD-pNA
for caspase 9. Caspase 3- and caspase 9-like activity was determined
by measuring substrate cleavage at 405 nm in a microplate reader
(SpectraMax Plus 384, Molecular Devices).
2.12. Determination of mtDNA copy number
Total DNA was extracted from brain cortical tissues using the TRIzol
Reagent (Sigma-Aldrich) according to the manufacturer's instructions.
Real-time qPCR analysis was performed to determine the mtDNA copyTable 2
Characterization of the experimental animal models.
Body weight (g) Brain weight (g)
Wistar 457.2 ± 24.70 2.29 ± 0.07
STZ 261.2 ± 10.72*** 2.16 ± 0.10
INS 332.2 ± 7.27*** # 2.05 ± 0.10
Data are themean ± SEM of 6 animals from each condition studied. Statistical signiﬁcance: ***p
###p b 0.001 when compared to the respective STZ diabetic rats.number as described by Fuke and collaborators [27], with slight modiﬁ-
cations. Relative quantiﬁcation of mtDNA levels was determined by the
ratio of the mitochondrial ND1 (mt-Nd1) gene to the single-copy,
nuclear-encoded beta-2-microglobulin (β2MG) gene. Reactions were
carried out in an iQ5 system (Bio-Rad), and the efﬁciency of the reac-
tions was determined for the selected primers using serial dilutions of
DNA samples. Primer concentration and annealing temperature were
optimized, and the speciﬁcity of the amplicons was determined by
melting curve analysis. The reaction mixture consisted of Maxima SYBR
Green qPCR Master Mix (Fermentas), sense and antisense primers (see
Table 1 for details), and 20 ng of DNA. Each reaction was run in triplicate
to calculate relative mtDNA copy number. Control values of all samples
were within the linear range. Control value differences were used to
quantify mtDNA copy number relative to the beta-2-microglobulin
gene with the following equation: Relative copy number = 2ΔCt,
where ΔCt is Ctβ2MG− CtND1.
2.13. Statistical analysis
Data regarding the characterization of the experimental animal
groups and mitochondrial function parameters are presented as mean
± SEM of the indicated number of animals and differences between
groups were analyzed using one-way ANOVA followed by Tukey's
post-hoc test. All other data are expressed as median ± interquartile
range of the indicated number of animals and statistical signiﬁcance
was determined using the non-parametric test of Kruskal–Wallis
followed by the post-hoc Dunn's multiple comparison test.
3. Results
3.1. Characterization of the experimental animal models
STZ animals present a signiﬁcant reduction in their bodyweight, and
a signiﬁcant increase in glycemia and glycated hemoglobin (HbA1c),
when compared to Wistar (W) control rats (Table 2), conﬁrming their
diabetic state. Compared to untreated STZ diabetic rats, diabetic rats
treated with INS present a statistically signiﬁcant increase in body
weight and a signiﬁcant reduction in glycemia and HbA1c levels,
which demonstrates the effectiveness of INS treatment in the ameliora-
tion of the diabetic phenotype. Additionally, a decrease in INS brain cor-
tical levels is observed in STZ animals, an effect that is partially reversed
by INS treatment (Fig. 1A). INS-treated rats show an increase in the
levels of brain glucose (Fig. 1B), although no statistically signiﬁcant al-
terations are observed in pyruvate levels (Fig. 1C).
3.2. Neither T1D nor INS treatment affect mitochondrial function
RCR is a measure of the coupling between substrate oxidation and
phosphorylation and is a good indicator of mitochondrial integrity.
ADP/O index shows the efﬁciency of themitochondrial phosphorylative
system [23]. Both mitochondrial indexes present no signiﬁcant differ-
ences between the experimental groups (Table 3). Also FCCP and
oligomycin respiratory states show no signiﬁcant differences between
the experimental groups (Table 3).
Mitochondrial membrane potential (ΔΨm) is generated through the
respiratory chain pumping of protons from the mitochondrial matrix toGlycemia (mg/dL) HbAlc (%)
92.60 ± 2.27 3.53 ± 0.03
502.5 ± 29.90*** 9.66 ± 0.53***
347.2 ± 36.61*** ## 6.15 ± 0.27*** ###
b 0.001when compared to the respectiveWistar control rats; #p b 0.05, ##p b 0.001 and
Fig. 1. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in brain cortical insulin (A), glucose (B) and pyruvate (C) levels. Data are the mean ± SEM of 5–6 animals from
each condition studied. Statistical signiﬁcance: $p b 0.05 when compared to the respective Wistar (W) control animals.
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chemical potential (Δp) resulting in a pH (ΔpH) and a voltage gradient
(ΔΨm) across the inner membrane. No statistically signiﬁcant differ-
ences are observed in ΔΨm and ADP-induced depolarization between
the three experimental groups of animals (Table 3). Lag phase is the
time necessary for mitochondria to phosphorylate the added ADP into
ATP. Again, no statistically signiﬁcant differences are observed between
the experimental groups (Table 3).
3.3. INS reverses mitochondrial ﬁssion promoted by T1D
Regarding mitochondrial fusion, no signiﬁcant alterations are
observed in Mfn1 (Fig. 2A), Mfn2 (Fig. 2B) and OPA1 (Fig. 2C) proteinTable 3
Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in brain cortical
mitochondrial respiration and oxidative phosphorylation system.
RCR
Re
sp
ir
at
or
y 
pa
ra
m
et
er
s
ADP/O
(nmol ADP/nAtgO/min/mg)
FCCP-stimulated
respiration
respiration
(nAtgO/min/mg)
(nAtgO/min/mg)
Oligomycin-inhibited
ΔΨm
(-mV)
(-mV)
ADP-induced
depolarization
Lag phase
(min)
4.65 ± 0.314
2.10 ± 0.299
97.39 ± 6.080
25.09 ± 4.070
185.4 ± 0.73
19.79 ± 1.51
0.97 ± 0.083
4.50 ± 0.157
2.10 ± 0.280
106.4 ± 23.64
29.12 ± 5.656
185.2 ± 2.73
20.21 ± 2.99
0.92 ± 0.053
4.51 ± 0.129
2.23 ± 0.201
100.1 ± 15.31
24.18 ± 3.451
184.8 ± 1.53
17.34 ± 0.80
0.88 ± 0.071
Wistar STZ INS
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n
Data are the mean ± SEM of 6 animals from each condition studied.levels. The mitochondrial ﬁssion-related protein Fis1 is statistically un-
altered between the experimental groups (Fig. 3A) however, the active
form of the ﬁssion protein DRP1 (PSer616-DRP1) is signiﬁcantly in-
creased in diabetic animals when compared to control animals, this ef-
fect being reversed by INS treatment (Fig. 3B).
3.4. INS treatment reverses T1D-induced mitochondrial biogenesis
alterations
Several transcription factors have been enrolled in the transcription
of genes that are crucial to mitochondria. To ascertain the role of T1D in
brain cortical mitochondrial biogenesis the protein levels of NRF1
(Fig. 4A), NRF2 (Fig. 4B) and TFAM (Fig. 4C) were evaluated. STZ-
induced T1D induces a signiﬁcant increase in the levels of NRF2
(Fig. 4B) and a slight increase in the levels of TFAM (Fig. 4C), these ef-
fects being reversed by INS treatment (Fig. 4A–C). Accordingly, a signif-
icant increase in the relative number ofmtDNA copies is observed in STZ
diabetic animals (Fig. 5). Again, INS treatment tends to normalize the in-
crease in the number of mtDNA copies induced by STZ-induced T1D
(Fig. 5).
3.5. INS therapy modulates autophagy
mTOR is a recognized repressor of the autophagic pathway. As
shown, the active form of mTOR (PSer2448-mTOR) (Fig. 6A) is not signif-
icantly altered in the three experimental groups. The same occurs with
the autophagic inducer Beclin1 (Fig. 6B) and the autophagic substrate
p62 (Fig. 6D). However, the levels of LC3-II, a gold-standard marker of
autophagic vesicle elongation, are tendentiously decreased by INS treat-
ment (Fig. 6C).
3.6. INS partially reverses tau protein phosphorylation promoted by T1D by
the increase in PP2A activity
To investigate whether T1D and INS treatment affect tau protein
phosphorylation, we evaluated the levels of tau protein phosphorylated
at residues Ser396 and Thr181. T1D increases the protein levels of
PSer396-Tau and decreases the protein levels of PThr181-Tau, while INS
partially reverses these effects (Fig. 7). The protein levels of some
Fig. 2. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the levels of mitochondrial fusion-related proteins: Mfn1 (A), Mfn2 (B) and OPA1 (C). Data are themedian ±
interquartile range of 6 animals from each condition studied.
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does not signiﬁcantly alter the levels of the active form of GSK3β
(PTyr216-GSK3β) (Fig. 8A and B), however INS treatment tends to reduce
the active form of this enzyme when compared to diabetic animals. AFig. 3.Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the levels ofmitocho
interquartile range of 6 animals from each condition studied. Statistical signiﬁcance: *p b 0.05slight decrease in the levels of the inactive form of GSK3β (PSer9-GSK3β)
is also observed in INS-treated rats (Fig. 8A and B). No signiﬁcant alter-
ations are observed in other kinases (JNK, ERK and p38 MAPK) known
to modulate tau protein phosphorylation (Fig. 8A and B). Although notndrialﬁssion-relatedproteins: Fis1 (A) and Pser616-DRP1/DRP1 (B). Data are themedian±
when compared to the respective Wistar (W) control animals.
Fig. 4. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the levels of transcription factors related with mitochondrial biogenesis: NRF1 (A); NRF2 (B) and TFAM
(C). Data are the median ± interquartile range of 6 animals from each condition studied. Statistical signiﬁcance: *p b 0.05 when compared to the respective Wistar (W) control animals.
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INS treatment signiﬁcantly increases the activity of this phosphatase
when compared to diabetic animals (Fig. 9).3.7. Neither T1D nor INS treatment alter brain cells survival and synaptic
integrity
The initiator caspase 9 is responsible for the mitochondrial-
dependent apoptotic cell death. Caspase 3 is an effector caspase involved
in both extrinsic and intrinsic (i.e. mitochondrial pathway) apoptosis
pathways. Both STZ-induced diabetes and INS treatment do not alter
caspases 9- and 3-like activities (Fig. 10A and B, respectively), which is
indicative of no effects on apoptotic cell death. Likewise, synaptophysin
and PSD95 levels are not altered in the three experimental groupsFig. 5. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the number of
copies of mitochondrial DNA (mtDNA). Data are the median ± interquartile range of 5
animals from each condition studied. Statistical signiﬁcance: **p b 0.01 when compared
to the respective Wistar (W) control animals.(Fig. 11A and B, respectively), which suggests that there is no signiﬁcant
loss of synaptic integrity.
4. Discussion
T1D patients critically depend on lifelong INS treatment to survive.
Indeed, T1D leads to several long-term complications due to the ex-
tremely high levels of blood glucose, which is expected to be controlled
by INS therapy [28–30].
STZ administration signiﬁcantly increased glycemia and HbA1c
levels and avoided bodyweight gain (Table 2). The daily s.c. administra-
tion of INS ameliorated the levels of blood glucose and HbA1c. Striking-
ly, INS treatment also induced a signiﬁcant body weight gain when
compared to diabetic animals (Table 2). The phenotypic effects induced
by STZ injection are comparable to those described by others in STZ-
induced diabetic animals [18,31,32] and T1D patients [33]. Neverthe-
less, the levels of glucose (Fig. 1B) and pyruvate (Fig. 1C) in cerebral cor-
tex of diabetic rats remained statistically unchanged suggesting that
glucose uptake and its metabolism by glycolysis are unaffected in this
animalmodel of T1D. Itwaspreviously reported that the function of glu-
cose transporter 1 (GLUT 1), the main glucose transporter found in the
blood–brain barrier (BBB), is not altered in cerebral microvessels of di-
abetic rats [34]. In addition, an increase in glucose use was reported
throughout the brain 1week after STZ administration in rats, while nor-
mal rateswere found 4 weeks after diabetes induction [35]. The system-
ic characterization of the INS-treated animals (Table 2) and the levels of
INS found in the brains of these animals (Fig. 1A) show the effectiveness
of the INS treatment. The increase in glucose levels in INS-treated dia-
betic rats is not related with alterations in glucose utilization since the
levels of pyruvate (Fig. 1C) and mitochondrial function (Table 3)
remained statistically unaltered. The increase in glucose levels in INS-
Fig. 6. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the levels of autophagy-related proteins: Pser2448-mTOR/mTOR (A), Beclin1 (B), LC3-II (C), p62 (D). Data are the
median ± interquartile range of 6 animals from each condition studied.
Fig. 7. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment on the ratio be-
tween phosphorylated (Thr181 and Ser396 residues) tau and total tau protein levels. Data
are the median± interquartile range of 6 animals from each condition studied. Statistical
signiﬁcance: *p b 0.05 when compared to the respective Wistar (W) control animals.
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moting glucose uptake into the brain.
INS treatment partially reversed the increase in the ratio of tau phos-
phorylated at Ser396 to total tau promoted by STZ-induced diabetes
(Fig. 7). Our results converge with other studies showing an increased
phosphorylation of tau protein in the brains of STZ diabetic animals
[36,37]. In vitro, pseudophosphorylation of Ser396 and Ser404 gener-
ates tau that is more ﬁbrillogenic [38]. Mutational studies with human
tau also showed that phosphorylation of tau at Ser396 is primarily re-
sponsible for the functional loss of tau-mediated tubulin polymerization
[39]. Interestingly, the ratio of tau phosphorylated at Thr181 to total tau
is decreased in the brain cortices of STZ diabetic animals (Fig. 7). A pro-
tective role for tau phosphorylation could be suggestedwhen thatmod-
iﬁcation take place at Thr181 [40], which could facilitate its binding to
exosomes and the release of tau excess [41]. Under these circumstances,
the decrease in the ratio of tau phosphorylated at Thr181 to total tau ob-
served in the brains of STZ-induced diabetic rats may indicate an in-
creased probability for an over accumulation and deposition of tau.
Several mechanisms modulate tau protein phosphorylation levels,
such as the decrease in the activity of PP2A, as observed in the brains
of STZ animals and spontaneous model of T1D, the non-obese diabetic
(NOD) mouse [36,37,42]. Accordingly, we observed a non-statistically
signiﬁcant decrease of PP2A activity in the cerebral cortex of STZ diabet-
ic rats (Fig. 9). It was also reported that the active form of p38-MAPK
was increased in neurons from the olfactory bulb of STZ diabetic rats,
which was accompanied by an increase in tau protein phosphorylation
[43]. Moreover, Clodfelder-Miller et al. [44] reported that STZ diabetic
animals present an increase in p38 MAPK and JNK active forms while
Fig. 8. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the phosphorylation of several kinases: GSK3β, JNK, ERK and p38 MAPK (A and B). Data are the
median ± interquartile range of 6 animals from each condition studied.
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Fig. 9. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the activity of
protein phosphatase 2A (PP2A). Data are the median ± interquartile range of 6 animals
from each condition studied. Statistical signiﬁcance: ##p b 0.01 when compared to the
respective STZ diabetic animals.
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ations were observed in the active forms of p38-MAPK and JNK
(Fig. 8A and B).
The decrease in the levels of phosphorylated tau protein promoted
by INS treatment can be explained, at least in part, by the slight
decrease in the levels of the active form of the Ser/Thr kinase GSK3β
(PTyr216-GSK3β) (Fig. 8A and B). Duarte et al. [45] showed that insulin
decreased PTyr216-GSK3β phosphorylation in vitro. Additionally, INS
treatment signiﬁcantly increased the activity of PP2A (Fig. 9), contribut-
ing to the normalization of the levels of phosphorylated tau protein. Ho
and collaborators [46] demonstrated that insulin and IGF-1 reduce tau
protein phosphorylation via the PI3-K pathway promoting its binding
to microtubules. It was also shown that intranasal administration of in-
sulin ameliorated tau protein phosphorylation in type 2 diabetic mice
[47].
Also, the slight decrease in LC3-II levels observed in INS-treated an-
imals (Fig. 6C), which suggest a decrease in autophagy, can be correlat-
ed with the decrease in tau protein phosphorylation via stimulation of
tau proteolysis by activation of calpains [48]. Indeed, Zhang et al.
[48] demonstrated that inhibition of autophagy with 3-methyladenineFig 10. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the caspase 9-
(A) and caspase 3-like (B) activities. Data are the median ± interquartile range of 5 ani-
mals from each condition studied.(3-MA) elicited an increased calpain activity and, concomitantly, a re-
duction in the levels of phosphorylated tau protein. The decrease in
LC3-II levels in INS-treated animals may result from the stimulation of
mTOR activity by INS [49]. However, unexpectedly, the levels of both
Pser2448-mTOR (Fig. 6A), an active form of the autophagy repressor,
and Beclin1 (Fig. 6B), an autophagy inducer, remained unaltered. None-
theless, it is noteworthy that mTOR phosphorylation does not always
correlate with its activity [50]. It has been also reported that the activa-
tion of mTOR may occur when one of the three residues (T2446, S2448
and S2481) is phosphorylated [51]. Additionally, p62, an autophagic
substrate, also remained unchanged in both experimental groups
when compared to the control group (Fig. 6 D). This result regarding
the levels of p62 is quite surprising taking into account the levels of
LC3-II (Fig. 6). Indeed, it is expectable that when autophagy is inhibited,
as suggested by the decrease in LC3-II in INS-treated animals (Fig. 6 C),
the levels of p62 increase [52]. However, p62 is also involved in
proteasomal degradation [53], which indicate that the relation between
autophagy and p62 levels is not always straightforward.
It has been described that tau protein hyperphosphorylation causes
mitochondrial dynamics abnormalities such as changes inmitochondri-
al distribution [54], andmitochondrial enlargement [55], which is puta-
tively due to an abnormal interaction between themitochondrialﬁssion
protein DRP1 and hyperphosphorylated tau protein [56]. In our model
of T1D, the expression pattern of the proteins involved inmitochondrial
fusion and ﬁssion is more compatible with enhanced mitochondrial
fragmentation due to increased phosphorylation of DRP1 at Ser616
(Fig. 3B). In agreement with our observations, increased mitochondrial
ﬁssion associated to increased protein levels of Fis1 and DRP1 was ob-
served in venous endothelial cells from patients with diabetes [57].
INS treatment reversed the increase in Pser616-DRP1 (Fig. 3B) promoted
by STZ-induced T1D. Also the observation that OPA1 protein levels
remained unaltered (Fig. 2C) in both STZ- and INS-treated animals is
consistent with the unaltered activity of caspases 9 and 3 (Fig. 10).
Only 10–15% of cytochrome c is found free in the intermembrane
space, while the major fraction can be found in the cristae [58,59].
OPA1 complexes are involved in cristae remodeling, and the assembly
and disassembly of such complexes regulates cytochrome c release
from inside the cristae, and therefore caspase-dependent apoptotic
cell death [60,61].
There is scarce evidence about the role of hyperglycemia in mito-
chondrial biogenesis, particularly in the central nervous system. A
nuclear-mitochondrial crosstalk regulates mitochondria biogenesis via
PGC1α-NRF1/2-TFAM [61,62]. Indeed, Edwards et al. [63] demonstrated
in amousemodel of type 2 diabetes (T2D)withwell-established diabet-
ic neuropathy, that neurons from the dorsal root ganglia (DRG) present-
ed greatermitochondrial biogenesis, when comparedwith non-diabetic
mice. Also in vitro experiments demonstrated that cultured DRG ex-
posed to hyperglycemic conditions exhibited increased mitochondrial
biogenesis [63,64]. The authors proposed that the increase inmitochon-
drial biogenesis is occurring in an attempt to overcome the metabolic
load induced by the hyperglycemic status as well as to compensate for
the enhanced mitochondrial fragmentation [63,64]. Accordingly, we
also observed an increase in mitochondrial biogenesis through the in-
crease in the levels of NRF2 (Fig. 4B) and TFAM levels (Fig. 4C) and
mtDNA copy number (Fig. 5) in T1D animals, those effects being nor-
malized by INS treatment. Studies performed in primary cultures of
mice hepatocytes revealed that prolonged exposure to INS decreased
the levels of NRF1, TFAM and the cellular mitochondrial content [65].
The alterations in mitochondrial biogenesis occurring in the cerebral
cortex of T1D animals may represent a compensation mechanism
against mitochondrial fragmentation, since there is no alteration of
mitochondrial function (Table 3) and no activation of the apoptotic cas-
cade (Fig. 10A and B), which protect synapse integrity, as demonstrated
by the maintenance of synaptophysin and PSD95 levels (Fig. 11), two
proteins crucial for neurotransmission and synaptic plasticity [66]. Ac-
cordingly, it has been recently demonstrated by our group, that
Fig. 11. Effects of T1D (STZ-induced diabetes) and insulin (INS) treatment in the protein levels of synaptophysin (A) and PSD95 (B). Data are themedian± interquartile range of 6 animals
from each condition studied.
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niﬁcant alterations neither in the respiratory chain nor in the phosphor-
ylation system [32].
5. Conclusions
Altogether our results support the idea that T1D modulates brain
cortical mitochondria through possible compensatory mechanisms
avoiding the decline of mitochondrial function, which is crucial for
brain cells integrity and survival. Nevertheless, STZ-induced diabetes in-
creases the abnormal phosphorylation of tau protein that in short- or
medium-term may predispose to neurodegenerative events. Our study
also shows beneﬁcial effects of INS therapy that is able to normalize or
attenuate brain cortical alterations promoted by STZ-induced T1D.
However, longer-term studies must be done to elucidate the impact of
T1D in brain biochemistry, structure and function. It would be also in-
teresting to study the effectiveness of INS therapy after a longer period
of time.
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